Primary CNS lymphoma

Nature Clinical Practice Neurology

Volumn 3, Issue 1, 2007, Pages 24-35

  Hochberg, Fred H ^a   Baehring, Joachim M ^b   Hochberg, Ephraim P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZATHIOPRINE; CARBOPLATIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; ETANERCEPT; ETOPOSIDE; FOLINIC ACID; GANCICLOVIR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOMUSTINE; MANNITOL; METHOTREXATE; PEMETREXED; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; TACROLIMUS; TEMOZOLOMIDE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNE DISEASE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; CANCER RELAPSE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR DYNAMICS; MONITORING; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; OVERALL SURVIVAL; PATHOGENESIS; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SALVAGE THERAPY;

CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA;

EID: 33846048765     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0395     Document Type: Review

References (85)

1. Central Brain Tumor Registry of the United States (2005) Statistical Report: Primary Brain Tumors in the United States 1998-2002 (Years Data Collected). [http://www.cbtrus.org/reports//2005-2006/2006report.pdf]
2. Jemal A et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-130
3. Olson JE et al. (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and end results analysis. Cancer 95: 1504-1510
4. Cingolani A et al. (2000) Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol 18: 3325-3330
5. Sacktor N et al. (2001) HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56:257-260
6. Bower M et al. (2006) Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst 98: 1088-1091
7. Filipovich AH et al. (1987) The Immunodeficiency Cancer Registry: A research resource. Am J Pediatr Hematol Oncol 9: 183-184
8. Castellano-Sanchez AA et al. (2004) Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 121: 246-253
9. Leblond V et al. (1998) Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 16: 2052-2059
10. Alderson L et al. (1996) Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry 60: 102-105
11. Drillenburg P and Pals ST (2000) Cell adhesion receptors in lymphoma dissemination. Blood 95: 1900-1910
12. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76: 301-314
13. Smith JR et al. (2003) Expression of B-cell-attracting chemokine 1 (CXCL 13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101: 815-821
14. Bashir R et al. (1992) Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain. J Neurooncol 12: 103-110
15. Aho R et al. (1997) Binding of malignant lymphoid cells to the white matter of the human central nervous system: Role of different CD44 isoforms, beta 1, beta 2 and beta 7 integrins, and L-selectin. J Neuropathol Exp Neurol 56: 557-568
16. Jahnke K et al. (2006) Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 24: 4754-4757
17. Larocca LM et al. (1998) The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 92: 1011-1019
18. Montesinos-Rongen M et al. (1999) Primary central nervous system lymphomas are derived from germinal cen,ter B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 155: 2077-2086
19. H gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 94: 1738-1746
20. Alizadeh AA et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511
21. Rosenwald A et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947
22. Rubenstein JL et al. (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107: 3716-3723
23. Pasqualucci L et al. (2001) Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412: 341-346
24. Montesinos-Rongen M et al. (2004) Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 103: 1869-1875
25. Papavasiliou FN and Schatz DG (2002) Somatic hypermutation of immunoglobulin genes: Merging mechanisms for genetic diversity. Cell 109 (Suppl 1): S35-S44
26. Schwindt H et al. (2006) Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol 65: 776-782
27. Weber T et al. (2000) Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 10: 73-84
28. Jordanova ES et al. (2002) Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 35: 38-48
29. Hochberg FH et al. (1983) Central-nervous-system lymphoma related to Epstein-Barr virus. N Engl J Med 309: 745-748
30. Cleary ML et al. (1985) Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science 228: 722-724
31. Ambinder RF (2000) Gammaherpesviruses and 'hit-and-run' oncogenesis. Am J Pathol 156: 1-3
32. Epeldegui M et al. (2007) Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Mol Immunol 44: 934-942
33. Smedby KE et al. (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98: 51-60
34. Zintzaras E et al. (2005) The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165: 2337-2344
35. Glass J et al. (1993) Intravascular lymphomatosis: A systemic disease with neurologic manifestations. Cancer 71: 3156-3164
36. Baehring JM et al. (2003) Neurolymphomatosis. Neuro-oncol 5: 104-115
37. Akpek EK et al. (1999) Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 106: 1805-1810
38. Buhring U et al. (2001) MRI features of primary central nervous system lymphomas at presentation. Neurology 57: 393-396
39. Moffat BA et al. (2005) Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102: 5524-5529
40. Macdonald DR et al. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280
41. Jahnke K et al (2006) International study on low-grade primary central nervous system lymphoma. Ann Neurol 59: 755-762
42. Gijtenbeek JM et al. (2001) Primary central nervous system T-cell lymphoma. Neurology 57: 716-718
43. Gleissner B et al. (2002) CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58: 390-396
44. Baehring JM et al. (2005) Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma. Cancer 104: 591-597
45. Baehring JM et al. (2006) Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J Neurol Sci 247: 208-216
46. Ivers LC et al. (2004) Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis 38: 1629-1632
47. Cingolani A et al. (1998) Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst 90: 364-369
48. Bataille B et al. (2000) Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 92: 261-266
49. Cher L et al. (1996) Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results. Neurology 46: 1757-1759
50. Batchelor T et al. (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21: 1044-1049
51. Ferreri AJ et al. (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90: 353-358
52. Doolittle ND et al. (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88: 637-647
53. DeAngelis LM et al. (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20: 4643-4648
54. Poortmans PM et al. (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21: 4483-4488
55. Nelson DF et al. (1992) Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9-17
56. Khan RB et al. (2002) Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 58: 175-178
57. Plotkin SR et al. (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10: 5643-5646
58. Enting RH et al. (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63: 901-903
59. Nguyen PL et al. (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23: 1507-1513
60. Soussain C et al. (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19: 742-749
61. Abrey LE et al. (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis. J Clin Oncol 21: 4151-4156
62. Forsyth PA et al. (1994) Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 44: 1473-1479
63. Newell ME et al. (2004) Human immunodeficiency virus-related primary central nervous system lymphoma: Factors influencing survival in 111 patients. Cancer 100: 2627-2636
64. Roychowchury S et al. (2003) Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 63: 965-971
65. Batchelor TT et al. (2003) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9: 711-715
66. Smith JR et al. (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109: 1709-1716
67. Fliessbach K et al. (2003) Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60: 563-568
68. Omuro AM et al. (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62: 1595-1600
69. Correa DD et al. (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62: 548-555
70. Harder H et al. (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62: 544-547
71. Neuro-oncological Working Group of the German Cancer Society [German] [http://www.neuroonkologie.de]
72. Phase IV study on the role of whole-brain radiation in the primary therapy of primary CNS lymphoma with high-dose methotrexate [German] [http://www.charite.de/haema-cbf/pcnsl.htm]
73. Issa S et al. (2006) Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis [abstract]. J Clin Oncol 24 (Suppl): A7595
74. Radiation Therapy Oncology Group [http://www.rtog.org]
75. Clinical Trials.gov [http://clinicaltrials.gov]
76. Memorial Sloan-Kettering Cancer Center, New York [http://www.mskcc.org]
77. Oregon Health & Science University [http://www.ohsu.edu]
78. Eastern Cooperative Oncology Group [http://www.ecog.org]
79. International Extranodal Lymphoma Study Group [http://www.ielsg.org]
80. National Cancer Institute Clinical Trials [http://www.cancer.gov/ clinicaltrials]
81. Panageas KS et al. (2005) Trends in survival from primary central nervous system lymphoma, 1975-1999: A population-based analysis. Cancer 104: 2466-2472
82. Abrey LE et al. (2000) Treatment for primary CNS lymphoma: The next step. J Clin Oncol 18: 3144-3150
83. McAllister LD et al. (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46: 51-60
84. Pels H et al. (2003) Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21: 4489-4495
85. Abrey LE et al. (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23: 5034-5043